FCSC News and Press, Fibrocell Science Inc. From 03/27/19

Thinly traded nano cap Fibrocell Science (NASDAQ: FCSC ) slips  18%  premarket on light volume on the heels of updated results from a Phase 1/2 clinical trial evaluating gene therapy FCX-007 in adults with recessive dystrophic epidermolysis bullosa (RDEB), an inherited disorder c...

Fibrocell Science (NASDAQ: FCSC ): FY GAAP EPS of -$1.45. More news on: Fibrocell Science, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

   - Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from Phase 1/2 clinical trial demonstrates FCX-007 continues to be well tolerated  with continued positive trends in wound healing - - Company repo...

Gainers:  Estre Ambiental (NASDAQ: ESTR ) +81% . Motif Bio plc (NASDAQ: MTFB ) +71% . Nevro (NYSE: NVRO ) +33% . Electrameccanica Vehicles (NASDAQ: SOLO ) +32% . Dragon Victory International (NASDAQ: LYL ) +21% . Fibrocell Science (NASDAQ: FCSC ) +18% . Amira Nature Foods (NYSE:...

Thinly traded nano cap Fibrocell Science ( FCSC +15.2% ) is up a whopping 49x surge in volume. Shares were up  66%  intraday ($3.28) before retracing. More news on: Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Motif Bio plc (NASDAQ: MTFB ) +55%  on iclaprim meeting with FDA. More news on: Motif Bio plc, China Bat Group, Inc., Nevro Corp., Stocks on the move, Read more ...

  - Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design  for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) -   - Company to highlight updated data from ongoing FCX-007 Phase 1/2 clinical trial for ...

EXTON, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will ...

Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in...

Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019  EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based th...